Article
Oncology
Maria Waltenberger, Denise Bernhardt, Christian Diehl, Jens Gempt, Bernhard Meyer, Christoph Straube, Benedikt Wiestler, Jan J. Wilkens, Claus Zimmer, Stephanie E. Combs
Summary: This article discusses the treatment options for brain metastases, including surgical resection and radiotherapy. The author compares the efficacy of hypofractionated stereotactic radiotherapy (HFSRT) and single fraction stereotactic radiosurgery (SRS) to determine the optimal radiotherapy scheme.
Review
Oncology
Kristin J. Redmond, Antonio A. F. De Salles, Laura Fariselli, Marc Levivier, Lijun Ma, Ian Paddick, Bruce E. Pollock, Jean Regis, Jason Sheehan, John Suh, Shoji Yomo, Arjun Sahgal
Summary: This critical review summarizes the literature specific to single-fraction stereotactic radiosurgery (SRS) and multiple-fraction stereotactic radiation therapy (SRT) for postoperative brain metastases resection cavities, providing practice recommendations. The data suggest high rates of local control with SRS/SRT for postoperative brain metastases, with SRS recommended as first-line treatment for eligible patients. Emerging data indicate that fractionated SRT may provide superior local control compared with single-fraction SRS for certain patient populations.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Michael Yan, Osbert Zalay, Thomas Kennedy, Timothy E. Owen, James Purzner, Shervin Taslimi, Teresa Purzner, Ryan Alkins, Nikitha Moideen, Andrea S. Fung, Fabio Y. Moraes
Summary: This study retrospectively analyzed data from patients with brain metastases treated with fractionated stereotactic radiotherapy (FSRT) without size restriction. The results showed that FSRT is safe and effective in the treatment of brain metastases of any size, with excellent local control and toxicity outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Eun Jung Lee, Kyu-Sun Choi, Eun Suk Park, Young Hyun Cho
Summary: HF-SRS results in better local control of large BMs and improved overall survival compared to SF-SRS, while simultaneously reducing the incidence of radiation toxicity.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
C. Evin, Y. Eude, J. Jacob, C. Jenny, R. Bourdais, B. Mathon, C. A. Valery, E. Clausse, J. M. Simon, P. Maingon, L. Feuvret
Summary: The purpose of this study is to report outcomes of patients with resected brain metastases treated with hypofractionated stereotactic radiotherapy (HSRT). The results showed local control, distant brain control, overall survival, leptomeningeal disease relapse, and radiation necrosis occurrence.
CANCER RADIOTHERAPIE
(2023)
Review
Oncology
Tyler Gutschenritter, Vyshak A. Venur, Stephanie E. Combs, Balamurugan Vellayappan, Anoop P. Patel, Matthew Foote, Kristin J. Redmond, Tony J. C. Wang, Arjun Sahgal, Samuel T. Chao, John H. Suh, Eric L. Chang, Richard G. Ellenbogen, Simon S. Lo
Summary: This article discusses the use of novel treatment techniques such as hypofractionated stereotactic radiotherapy (HSRT) and pre-operative SRS for large brain metastases, which can improve local control rates and reduce the occurrence of LMD and RN.
Article
Oncology
Sergej Telentschak, Daniel Ruess, Stefan Grau, Roland Goldbrunner, Niklas von Spreckelsen, Karolina Jablonska, Harald Treuer, Martin Kocher, Maximilian Ruge
Summary: The study retrospectively analyzed 34 patients treated with CK-hSRS, showing good treatment effectiveness with high local control rates but a 12% complication rate.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sten Myrehaug, John Hudson, Hany Soliman, Mark Ruschin, Chia-Lin Tseng, Jay Detsky, Zain Husain, Julia Keith, Eshetu G. Atenafu, Pejman Maralani, Chris Heyn, Sunit Das, Nir Lipsman, Arjun Sahgal
Summary: This study aimed to report mature image-based outcomes for MLC-Linac HSRT, focusing on clinical and dosimetric factors associated with local failure (LF). The results showed that daily 5-fraction 30Gy HSRT treatment can achieve optimal local control, irrespective of tumor volume and histology, with an acceptable risk of radiation necrosis.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Angela Barillaro, Mara Caroprese, Laura Cella, Anna Viggiano, Francesca Buccelli, Chiara Daponte, Chiara Feoli, Caterina Oliviero, Stefania Clemente, Antonio Farella, Manuel Conson, Roberto Pacelli
Summary: Brain metastases are severe events in patients with solid tumors. Stereotactic radiation therapy is an effective treatment for brain metastases, but it may lead to radiation necrosis, which can impact patient's quality of life. Prompt recognition and treatment are necessary for managing radiation necrosis.
Article
Oncology
Michael Yan, Minha Lee, Sten Myrehaug, Chia-Lin Tseng, Jay Detsky, Hanbo Chen, Sunit Das, Collins Yeboah, Nir Lipsman, Leodante Da Costa, Lori Holden, Chinthaka Heyn, Pejman Maralani, Mark Ruschin, Arjun Sahgal, Hany Soliman
Summary: This study aimed to report the outcomes of salvage hypofractionated stereotactic radiosurgery (HSRS) for brain metastases that failed prior HSRS/SRS. The results showed that HSRS can effectively control local failures and has low toxicity rates.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Xue-Yi Xie, Hong-Hua Peng, Xi Zhang, Yu-Liang Pan, Zhen Zhang, Pei-Guo Cao
Summary: This study evaluated the clinical outcomes of hypofractionated stereotactic radiotherapy (HFSRT) combined with whole brain radiotherapy (WBRT) in patients with brain metastases (BMs). The results showed that this treatment modality has a high success rate in achieving intracranial local control without severe acute toxicities. Factors such as KPS score and tumor volume significantly influenced the overall survival rate.
RADIATION ONCOLOGY
(2022)
Article
Clinical Neurology
Michael Ortiz, Joseph Herbert, Busha Hika, Gregory Biedermann, Leslie Phillips, Amelia Wexler, N. Scott Litofsky
Summary: This study reviewed the efficacy and complications of hypofractionated stereotactic radiotherapy (hSRT) in treating metastases involving the brainstem. The results showed that hSRT had similar rates of survival, tumor control, and toxicity compared to single fraction radiotherapy. Dose escalation near the brainstem can be considered with a hypofractionated regimen of 5 fractions.
JOURNAL OF CLINICAL NEUROSCIENCE
(2022)
Article
Oncology
Enrica Seravalli, Michelle Sierts, Eric Brand, Matteo Maspero, Szabolcs David, Mariellen E. P. Philippens, Eduward H. J. Voormolen, Joost J. C. Verhoeff
Summary: This work investigated the dosimetric feasibility of MRL-based post-operative radiosurgery for brain metastases. The results showed that direct post-operative MRL treatment for resection cavities of brain metastases is dosimetrically acceptable, with the advantages of increased patient comfort and improved logistics. However, further investigation is needed to determine the clinical benefits of this workflow.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Clinical Neurology
Cristian Udovicich, Sweet Ping Ng, Damien Tange, Nola Bailey, Neda Haghighi
Summary: Compared with postoperative stereotactic radiosurgery, neoadjuvant stereotactic radiosurgery leads to comparable local control with a decreased risk of leptomeningeal disease and radionecrosis.
OPERATIVE NEUROSURGERY
(2022)
Article
Oncology
Christine Kornhuber, Stephan Ensminger, Patrick Huebsch, Martin Janich, Chris Andre Leucht, Dirk Vordermark, Christian T. Dietzel
Summary: In stereotactic radiotherapy, a simultaneously integrated boost (SIB) approach was tested against the classical prescription for 20 unresected brain metastases. The SIB concept was found to better define the dose distribution inside the planning target volume (PTV) and can be considered for clinical use.
RADIATION ONCOLOGY
(2023)
